DRUG · Unmapped registry intervention
PT-112
Find medicine records ·
Find other trials using this name
Clinical trial
An Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study
NCT02884479
Drugs and interventions used in this trial
2 registeredThese interventions are listed by ClinicalTrials.gov. An RxNorm link indicates a mapped medicine record; the registry name alone is not proof of a specific branded formulation.
DRUG · Mapped RxNorm record
Docetaxel
Normalized identity: docetaxelView linked drug · Find medicine records ·
Find other trials using this name
No matching interventions in this trial.
Study at a glance
Registry-backedAn Open-Label Phase I/II Clinical Study of PT-112 in Combination With Docetaxel in Subjects With Advanced Solid Tumor in a Phase I Dose Escalation Study and in Subjects With Non-Small Cell Lung Cancer (NSCLC) in a Phase II Dose Confirmation Study
Design: INTERVENTIONAL · Status: UNKNOWN · Phase: PHASE1, PHASE2
Read study objectives, eligibility and outcome measures at ClinicalTrials.govAdvertisement
Conditions
Advanced Solid Tumorunresolved
Interventions
PT-112DRUG
DocetaxelDRUG · verified · RxNorm: docetaxel
Sponsors & collaborators
Parexelcollaborator
National Cheng-Kung University Hospitalcollaborator
Mapped research locations
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT02884479 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.